CANNAPHARMARX, INC. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how CannaPharmaRx, Inc. (CPMD) performed this year. My goal is to turn complex filing data into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

CannaPharmaRx is an Alberta-based company that grows and processes medical and craft cannabis. They operate a 55,000-square-foot facility in Cremona, Canada, built for high-density growing. They hold federal licenses from Health Canada to grow, process, and sell medical cannabis. To maintain these operations, they employ specialized staff, including a Master Grower and a Quality Assurance Person, to ensure they remain in compliance with federal cannabis regulations.

2. Financial performance

The company is currently in a "build-out" phase and generates minimal revenue from its operations. They recently wrote off a $4.5 million investment in LTB Management, which was intended to facilitate an expansion into European e-commerce. This write-off resulted in a total loss, significantly impacting the company’s balance sheet and contributing to a substantial accumulated deficit.

3. Major wins and challenges

The company’s primary hurdles are debt management and cash flow. They are currently in default on a $1.2 million royalty agreement with Koze Investments. While Koze has agreed to a forbearance period until May 31, 2026, this default highlights the company’s struggle to generate sufficient cash from daily operations to meet its financial obligations.

4. Financial health

The company’s financial position is precarious. With over 678 million shares currently issued, investors face a high risk of dilution. Because the company lacks steady income and struggles to pay existing debts, they rely on issuing additional shares to raise necessary capital. This process increases the total share count, which lowers the value of your individual stake and reduces potential earnings per share.

5. Future outlook & Regulatory Hurdles

Management is focused on increasing production and obtaining "EU-GMP" certification, which is a requirement to export medical cannabis to high-margin European markets. However, they operate in a strictly regulated environment:

• Regulatory Costs: The industry faces high federal excise taxes, which can consume up to 30% of gross revenue, leaving narrow profit margins for craft producers.
• Compliance: The company must adhere to rigorous Health Canada standards regarding packaging, security, and product testing. Changes in law or failure to meet these standards could result in significant unplanned expenses.

6. Key risks

• Debt Default: The current default on a major loan is a significant indicator of financial instability.
• Dilution: The company’s reliance on equity financing to fund its European certification goals will likely lead to further share issuance, which negatively impacts existing shareholders.
• Regulatory Environment: Cannabis laws are constantly evolving. Government reviews of tax structures and potential restrictions on high-potency products could limit the company’s product offerings and increase operational costs.

Bottom Line: This is a high-risk, speculative investment. The company faces significant challenges, including a lack of consistent cash flow, a history of failed investments, and an ongoing default on debt. While they possess the necessary licenses to operate, their path to profitability is hindered by heavy taxation and a persistent need to issue more shares to stay afloat. Before investing, consider whether the potential for European market entry outweighs the current financial instability and the high likelihood of further dilution.